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Abstract Four monoclonal antibodies (MAbs) recognizing
HIV-1 reverse transcriptase (RT) were shown here to cross-
react with the LP subunit of Escherichia coli RNA polymerase
(RNAP). The anti-RT MAbs bind to a peptide comprising
residues 294^305 of the RT amino acid sequence. Computer
analyses revealed sequence similarity between this peptide and
two regions of the RNAP LP subunit. MAb-binding studies using
RT mutants suggested that the epitope is located to amino acids
652^663 of the LP sequence. One of the MAbs which inhibited the
polymerase activity of RT also mediated a dose dependent
inhibition of the RNAP activity. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Escherichia coli RNA polymerase (RNAP) and human im-
munode¢ciency virus type 1 (HIV-1) reverse transcriptase
(RT) are polymerases which functionally work in opposite
directions. RT catalyzes the synthesis of double-stranded
(ds) DNA using the viral single-stranded (ss) RNA as tem-
plate [1,2] while RNAP uses dsDNA as template for ssRNA
synthesis. HIV-1 RT is composed of two subunits with mo-
lecular weights of 66 and 51 kDa (p66 and p51), where the
amino acid sequence of p51 is identical to the N-terminal
sequence of p66 [3^5]. All catalytic activities have been as-
signed to the p66 subunit of the heterodimer [6^8].
E. coli RNAP contains a catalytic core of two identical K
subunits (40 kDa), one L subunit (150 kDa) and one LP sub-
unit (160 kDa). In vitro the enzyme can utilize dsDNA and
ssDNA molecules as template for synthesis of ssRNA and
DNA^RNA hybrids, respectively. Part of the catalytic site
for polymerization resides in the L subunit of the RNAP
[9,10], but also the LP subunit, the most basic of the RNAP
subunits, has been shown to bind DNA in vitro and to be
involved in the catalytic activity [11^13]. The sequence of LP
comprises 1407 amino acids and contains eight conserved seg-
ments denoted A^H with segment A being characterized by a
zinc ¢nger motif [14] and region C by a DNA polymerase
motif [15].
The crystal structures of several small polymerases includ-
ing HIV-1 RT, have revealed a common three dimensional
(3D) structure resembling a right hand where ¢nger-, palm-
and thumb sub-domains form a cleft which accommodates the
substrate [16^21]. A similar active site cleft was visualized by
electron crystallography for the E. coli RNAP holoenzyme as
well as for the RNAP II from yeast [22^24]. Besides their 3D
structural similarity, RT and RNAP share another similar
feature. Both enzymes bind to ss templates generating a tran-
sient DNA^RNA hybrid. In this study, cross-reactivity of
four anti-RT monoclonal antibodies (MAbs) with the
RNAP LP subunit is reported. Comparison of the MAb-bind-
ing RT sequence with the sequence of LP revealed a potential
common epitope. Inhibition of both the RT and RNAP ac-
tivity by the same anti-RT MAb further indicated that this
epitope is part of a region which is involved in the catalytic
activity of the two polymerases.
2. Materials and methods
2.1. MAbs and synthetic peptides
Production and characterization of the anti-RT MAbs as well as
the synthetic peptide, Pep 1 (aa (amino acid) 294^318), were previ-
ously described [25] (Table 1A). All MAbs recognized both the p66
and p51 subunits of RT in Western blot analysis. The MAb-binding
epitopes were mapped to the following RT regions: aa 193^284
(11G10), aa 294^318 (31D6, 31G8, 32E7, 33D5, 5B2) and aa 334^
410 (7D8). The synthetic peptides Pep 2 (aa 294^305) and 3 (aa 306^
318) were provided by H.C. Holmes, Medical Research Council, Lon-
don, UK.
2.2. Enzymes used for testing cross-reactivity
The following DNA-binding enzymes were used for testing the
MAbs for cross-reactivity in enzyme-linked immunosorbent assay
(ELISA): E. coli RNAP, T4 RNAP, E. coli DNA polymerase, T4
DNA polymerase, Acinetobacter calcoaceticus DNA polymerase and
DNase, E. coli Exo III, E. coli Endo III, and an AP endonuclease
from MPC cells (all provided by J.R. Lillehaug, University of Ber-
gen); Sp6 RNAP, T7 RNAP, E. coli RNaseH and AMV-RT (all from
Promega); bovine RNaseA and bovine DNase I (Sigma) and
MoMLV-RT (Stratagene). In addition, a Western blot kit for HIV-
2 (Pasteur) and an ELISA kit for HTLV-I (Du Pont) were employed
for testing with HIV-2 and HTLV-I RT, respectively.
2.3. ELISA and Western blot analysis
In ELISA, at least 200 ng of protein was used for coating of each
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microtiter plate well. In Western blot analysis, E. coli proteins from
crude lysates were separated on 7% sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) [26] and electrophoretically
transferred onto nitrocellulose membranes (0.45 Wm, Schleicher and
Schuell) [27]. Binding of anti-RT MAbs was detected as described
[25]. E. coli (XL-1 Blue) strains harboring the plasmids pMKSe2
and pT7LP which over-express the RNAP L and LP subunits, respec-
tively, were provided by K. Severinov, The State University of New
Jersey. Growth of bacteria and induction of the lac and lac UV5
promotor were performed as described [9,28]. Bacteria were disrupted
by freezing followed by incubation at 37‡C for 1 h in a bu¡er con-
taining 10 mM sodium phosphate pH 7.2, 8 M urea, 1% SDS and 1%
L-mercaptoethanol. No insoluble material was visible after this treat-
ment.
2.4. Computer-assisted analysis
Comparisons of the protein sequences of the HIV-1 Pol polyprotein
(consisting of protease, RT and integrase; HXB2 isolate, SWISS-
PROT accession no. P04585) and the E. coli RNAP LP subunit
(SWISS-PROT accession no. P00577) were performed with the pro-
gram Compare. Segments in common between the sequences were
visualized with the program DotPlot. The program BestFit was
used to determine regions in the RNAP LP subunit sequence with
the highest similarity to a de¢ned RT segment. The programs are
part of the Wisconsin Sequence Analysis Package, Version 10.0 (Ge-
netics Computer Group, Inc., Madison, WI, USA; URL: http//
www.gcg.com/); they were run on a server at the Norwegian EMBnet
node (URL: http://www.no.embnet.org/).
2.5. Site-speci¢c mutagenesis
For site-speci¢c mutagenesis of the RT protein, the recombinant
circle polymerase chain reaction (PCR) method was applied [29].
The plasmid pRSETART, a derivative of pRSETA (Invitrogen) con-
taining the RT coding region from a HIV-1 HXB2 isolate (EMBL
database accession no. K03455) was used as template; circular per-
muted molecules of pRSETART were generated using the ‘outside’
primers 5P-TGGTTCCTCTAAGGAGTTTACATAATTGCC and 5P-
GAGATTCTAAAAGAACCAGTACATGGAGTG (with their 5P
ends corresponding to HIV-1 HXB2 antisense nucleotide 6312 and
sense nucleotide 3471, respectively) and the following mutating prim-
ers (mutations underlined) and their reverse complements: 5P-TAC-
CACTAACATTAGAGGCCGAGCTAGAAC (corresponding to
HIV-1 HXB2 antisense nucleotides 3427^3456, for mutant Mut 1),
5P-TACCACTAACATTAGAGGCCCAGCTAGAAC (correspond-
ing to HIV-1 HXB2 sense nucleotides 3427^3456, for Mut 2), 5P-
AAGAAGCAGAGGCCGAAGTGGCAGAAAACAGAG (corre-
sponding to HIV-1 HXB2 sense nucleotides 3439^3471, for Mut 3
construction). Recombinant DNA circles formed from the permuted
molecules via de- and renaturation were transformed into E. coli
strain JM109. The mutations create an additional HaeIII restriction
site used to select the desired clones. The mutations were veri¢ed by
DNA sequencing. PCR ampli¢cation was performed on a DNA Ther-
mal Cycler (Perkin-Elmer). Taq DNA polymerase was purchased
from Stratagene. The DNA sequencing kit, plasmid miniprep kit
and HaeIII restriction enzyme were from United States Biochemicals,
Qiagen and New England BioLabs, respectively. Oligonucleotides
were synthesized on a PCR-MATE 391 DNA synthesizer (Applied
Biosystems).
2.6. RNAP assay
The enzyme assay was performed in transcription bu¡er (Promega)
with a ¢nal concentration of 25 U/ml RNasin, 0.9 mM dithiothreitol,
0.2 mM of each ATP, GTP and CTP, 0.1 mM unlabelled UTP, 1 Wg/
ml PhiX174 ssDNA (Bethesda Research Lab.) or PhiX174 dsDNA
(Promega), 50 WCi/ml [3H]UTP (NEN, 35.2 Ci/mmol) and 50 Wg/ml
(7.6 U/ml) RNAP (Promega). Aliquots of 10 Wl were removed from
the reaction mixture and spotted on DE81 ¢lters (Whatman) after 15,
30, 60 and 120 min reaction time at 37‡C. The ¢lters were air-dried,
washed with 2USSC (twice) and ethanol (twice), dried and counted in
a liquid scintillation counter. For inhibition of RNAP, the enzyme
was pre-incubated with di¡erent amounts of anti-RT MAb 31D6
(0.75^6 Wg/ml) overnight at 4‡C. As a negative control, the same
amount of an anti-TrpE MAb was used [25].
3. Results
3.1. Cross-reactivity of anti-RT MAbs
In order to detect similarities between HIV-1 RT and other
DNA- and RNA-binding proteins, a panel of 20 anti-RT
MAbs recognizing ¢ve di¡erent epitopes of RT [25] were
tested in ELISA using total E. coli lysates and the enzymes
Table 1
Reaction patterns of anti-RT MAbs with synthetic peptides and RT mutants
MAbs (epitopes)
11G10
(193^284)
31D6
(294^318)
31G8 32E7 33D5
(294^318)
5B2
(294^318)
7D8
(334^410)
A: RT peptides
Pep 1: aa 294^318 PLTEEAELELAENREILKEPVHGVY 3 + + + 3
Pep 2: aa 294^305 PLTEEELELAE 3 + + 3 3
Pep 3: aa 306^318 NREILKEPVHGVY 3 3 3 + 3
B: RT mutants
Mut 1: 294-PLTLEAELELAE-305 + 3 ND + +
Mut 2: 294-PLTLEAQLELAE-305 + 3 ND 3 3
Mut 3: 294-PLTEEAEAEVAE-305 + + ND + +
ELISA was used to detect MAb-binding to the peptides (A). Western blot was used to detect binding to the mutants (B). Amino acid residues
are written with their single-letter abbreviation, mutations are in bold. +/3 denotes binding/no binding. ND, not tested.
Fig. 1. Western blot analysis of E. coli XL-1 Blue strains over-ex-
pressing the LP (A) and L (B) subunits. Lanes 1 (A and B), proteins
stained by amido black; lanes 2 (A and B), proteins detected by
MAb 31D6; lanes 3 (A and B), proteins detected by MAb 31G8.
The molecular weights of pre-stained high molecular weight stan-
dard proteins (Bio-Rad) are indicated to the right of lanes 3.
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listed in Section 2.2 as antigens. Cross-reaction was observed
for anti-RT MAbs 31D6, 31G8, 32E7 and 33D5 with E. coli
RNAP, T4 RNAP and E. coli lysates. T4 RNAP contains the
E. coli host RNAP K, L and LP subunits. The results therefore
indicated a speci¢c binding of the MAbs to the E. coli RNAP
core enzyme. The particular RNAP subunit recognized by the
MAbs was determined by Western blot analysis using bacte-
rial strains over-expressing either the L or LP subunit of
RNAP (Fig. 1). The molecular weight and relative amounts
of the LP and L subunits are shown by amido black staining in
lanes 1 (Fig. 1A,B). Lanes 2 and 3 (Fig. 1A,B) demonstrate
binding of the MAbs (31D6 and 31G8, respectively) to the LP
subunit. Binding generated solid bands with the LP over-ex-
pressing strain (Fig. 1A) and can even be detected with the L
over-expressing strain as thin bands visible above the position
of the L subunit. Such thin bands demonstrating cross-reac-
tivity of the MAbs with the LP subunit were also observed by
Western blot analysis of the E. coli strain HB101 (not shown).
3.2. RT peptides recognized by the anti-RT MAbs
It was previously shown that the MAbs 31D6, 31G8, 32E7,
33D5 and 5B2 bind to a synthetic peptide comprising aa 294^
318 of the HIV-1 RT sequence [25] (Pep 1; Table 1A). In this
study, two synthetic peptides consisting of the N- and C-ter-
minal halves of Pep 1 (Pep 2, aa 294^305, and Pep 3, aa 306^
318, respectively) were used in order to determine the se-
quence recognized by the MAbs more precisely and, further-
more, to di¡erentiate between the MAbs. Binding to peptide
Fig. 2. Dot-plots visualizing the similarity between the HIV-1 RT and E. coli RNAP LP subunit amino acid sequences. The HIV-1 Pol polypro-
tein sequence (vertical axis; RT from position 156 to 721) and the E. coli RNAP LP subunit sequence (horizontal axis) were compared in any
possible register using a window size of 12. Dots in the upper plot represent window scores meeting a high match criterion (a stringency of 25)
above which almost all scores are ¢ltered out; dots in the two lower plots (enlargement of the relevant segments) represent window scores
greater than or equal to 8. Dots are positioned in the middle of the window on both axes. The scores are determined by summing the match
values for each pair of residues within the window at each window position using the default PAM-250 matrix (see program documentation).
Amino acid residues along the axes of the lower plots are written with their single-letter abbreviations. Residues on shaded background com-
prise the potential RT and RNAP LP subunit epitopes.
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Pep 2 was demonstrated for the MAbs 31D6, 31G8, 32E7 and
33D5 and binding to peptide Pep 3 for the MAb 5B2 (Table
1A). In contrast to the ¢rst four MAbs, MAb 5B2 did not
recognize the RNAP LP subunit.
3.3. Sequence comparison of RT and the RNAP LP subunit
In order to determine whether the cross-reactivity of the
anti-RT MAbs with RNAP LP is re£ected at the primary se-
quence level of the two proteins, a computer-assisted sequence
comparison was performed using the programs Compare and
DotPlot. Similar segments in the two sequences according to
highly stringent match criteria are indicated by dots in the
upper dot-plot of Fig. 2. Interestingly, of the three most pro-
nounced signals remaining under these conditions (circled),
two are from pairs of matching sequence segments both in-
volving the RT peptide sequence recognized by the cross-re-
acting MAbs (arrows; see enlargements in the lower dot-
plots). The RNAP LP subunit partner segments in the pairs
are the sequences 471-PLTLEAQLEARA-482 and 652-EII-
SEAEAEVAE-663, with residues having identical or similar
counterparts in the RT Pep 2 sequence written in bold. Sup-
port for the signi¢cance of this ¢nding was provided by an-
other comparison procedure, the program BestFit, which re-
veals the optimal alignment of the best segment of similarity
between two sequences. When running the program repeat-
edly with sequence pairs containing the RT Pep 2 sequence
and overlapping segments of the RNAP LP subunit sequence
250 amino acids in length, the best RT Pep 2 sequence partner
found within RNAP LP according to quality-score calculation
by the program is a segment included in the aa 471^482 por-
tion, succeeded by a segment included in the aa 652^663 por-
tion (data not shown).
3.4. Binding of the MAbs to RT mutants
Mutations were introduced into the RT sequence in order
to determine which of the LP amino acid residues were recog-
nized by the cross-reacting anti-RT MAbs (Table 1B). The
mutations rendered the RT sequence aa 294^305 more similar
to the RNAP LP sequences 471-PLTLEAQLEARA-482 (Mut
1 and Mut 2) and 652-EIISEAEAEVAE-663 (Mut 3) found as
best hits in sequence comparison. Binding of MAb 31D6 was
abolished by the mutations in Mut 1 and 2. MAb 11G10
binding to an epitope located N-terminal to the mutated se-
quence recognized both mutants whereas MAbs 5B2 and 7D8
binding to epitopes located C-terminal recognized Mut 1 but
not Mut 2. This indicated that the second of these mutations
introduced conformational changes also in the epitopes of
these MAbs. Mutant Mut 3, in contrast, was recognized by
MAb 31D6 which strongly suggested that residues within the
LP sequence 652-EIISEAEAEVAE-663 accounted for binding
of MAb 31D6 to the LP subunit. Furthermore, binding also of
the other MAbs indicated that the folding of the RT epitopes
recognized by them was not a¡ected by the mutations in Mut
3.
3.5. Inhibition of RNAP by anti-RT MAb 31D6
MAb 31D6 was previously shown to inhibit the polymerase
activity of RT while no inhibition of the RNaseH activity was
observed. This indicates that inhibition of the RT polymerase
activity was not a result of any unspeci¢c e¡ect [25]. RNAP
assays were performed in the presence of MAb 31D6 or a
non-speci¢c anti-TrpE MAb in order to determine if the re-
gions in RNAP LP responsible for the cross-reactivity of the
MAbs mediate a functional similarity in the two enzymes.
RNAP was incubated with the MAbs prior to addition of
the substrates. Using ss PhiX DNA as template, inhibition
was demonstrated both by kinetic analysis (Fig. 3A) and by
a dose^response assay (Fig. 3B). A signi¢cant inhibition of
RNAP activity by MAb 31D6 was also observed by kinetic
analysis using the ds PhiX DNA as template (not shown).
4. Discussion
Computer-assisted search for similarities between protein
sequences is based upon comparing chemical and biological
properties of their amino acid residues. For the described
Fig. 3. Inhibition of RNAP activities by MAb 31D6. A: Kinetics of
in vitro RNAP activity with ssDNA template in the presence of
MAb 31D6 or an anti-TrpE MAb. Before being tested for activity,
2 Wg RNAP was incubated overnight at 4‡C with the 0.4 Wg MAbs.
B: Dose^response dependent inhibition of RNAP activity with
ssDNA template in the presence of MAb 31D6. The activity of
RNAP was de¢ned as 100% activity after pre-incubation with the
same amount of anti-TrpE MAb.
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polymerases, this has been insu⁄cient to prove the evolution-
ary relationship between them [21]. Antibodies, on the other
hand, recognize 3D structures on the surface of antigens and
therefore can be considered as complementary tools for pro-
tein relationship analysis. Amino acid residues of the hyper-
variable domains of the antibody molecule interact with res-
idues of the antigenic epitope. Still, mapping of epitopes using
synthetic peptides is usually unsuccessful. This may be be-
cause the folding of peptides does not mimic the conformation
of the epitope or because the number of amino acid residues
in the peptide is insu⁄cient for binding. The cross-reacting
anti-RT MAbs presented in this study, however, recognized
a synthetic peptide consisting of the RT amino acid residues
294-PLTEEAELELAE-305. According to the 3D model of
the RT structure, this sequence is located on K-helix J in
the thumb sub-domain of both the p66 and p51 subunits. In
p66, the thumb sub-domain is involved in the formation of
the polymerase cleft. In the p51 subunit, on the other hand, K-
helix J participates in dimer formation and is not part of the
structural elements that make potential contacts with DNA
[16^18]. It cannot be concluded from the present study which
of the subunits or whether both of them are subjected to in-
hibition by MAb 31D6.
Cross-reactivity of the anti-RT MAbs with the LP subunit of
E. coli RNAP suggests a structural similarity of the two en-
zymes. Having de¢ned the speci¢c RT sequence recognized by
the MAbs made it possible to search for sequence similarity in
the sequence of RNAP LP. Computer-assisted analysis re-
vealed the LP sequences 471-PLTLEAQLEARA-482 and
652-EIISEAEAEVAE-663 as the ¢rst and second best best
matching hits. Site-directed mutagenesis of the RT sequence
then demonstrated that the second LP sequence (652^663) was
recognized by the anti-RT MAb 31D6. This sequence is lo-
cated in the conserved region E of the LP subunit [14]. Inter-
estingly, another study based on a complementary assay using
an E. coli strain unable to synthesize the LP chain at 37‡C
showed that the mutation of a residue within this sequence
(E656) rendered the enzyme recessive negative [11]. Inhibition
of RNAP by the anti-RT MAb 31D6 con¢rms the functional
importance of this LP region. Furthermore, inhibition of both
HIV-1 RT and E. coli RNAP by the same anti-RT MAb
suggests common functional properties of the two enzymes.
From the results of this study, it is likely that they are at least
partly determined by the sequences recognized by MAb 31D6,
i.e. the sequence 294-PLTEEAELELAE-305 in HIV-1 RT and
652-EIISEAEAEVAE-663 in the E. coli RNAP LP subunit.
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